Kilitch Drugs (India) Ltd
Ticker: KILITCH
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
355.25
Market Cap
621.00
Debt/Equity
0.2465
ROE %
14.203
PB
3.0979
Promoter %
69.232
Pledge %
0.000
1Y Rev Growth %
31.873
5Y Rev Growth %
29.530
NP Margin %
12.751
NP Margin 5Y Avg %
8.138
Trading Reference
1M Return %
-0.669
6M Return %
7.786
1Y Return %
9.957
% Away 52W High
40.746
% Away 52W Low
21.028
Daily Volume
2933
Investment Verdict
Hold
Score 68/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 24/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Kilitch Drugs (India) Ltd is currently trading near a key support level, with recent volume trends indicating potential bullish momentum. If it breaks above the resistance level identified at ₹X, there is a strong probability of reaching ₹Y in the medium term. Conversely, if it falls below the support level, a decline to ₹Z is possible.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
E
Emami Paper Mills Ltd
Emami Paper Mills Ltd presents several risks with inconsistent growth and profitability metrics, and market sentiment is currently unfavorable.
View details
S
Sutlej Textiles and Industries Ltd
Sutlej Textiles shows moderate potential with consistent growth, but faces challenges in profitability and valuation metrics.
View details
S
Shiv Texchem Ltd
Shiv Texchem Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns.
View details
M
Mishtann Foods Ltd
Mishtann Foods Ltd shows potential in a growing sector, but faces challenges in consistency and execution.
View details
A
Asian Hotels (North) Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
H
Hindustan Media Ventures Ltd
Hindustan Media Ventures Ltd shows potential in a transforming sector, but faces challenges in growth consistency and valuation metrics.
View details
M
M V K Agro Food Product Ltd
M V K Agro Food Product Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
L
Lakshmi Mills Company Ltd
Lakshmi Mills Company Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
P
Pyramid Technoplast Ltd
Pyramid Technoplast Ltd shows potential for growth in a favorable sector, but execution risks and liquidity concerns should be monitored.
View details
S
Sil Investments Ltd
Sil Investments Ltd presents several risks with limited growth prospects and inconsistent financial performance, making it a risky investment.
View details
K
Kaya Ltd
Kaya Ltd presents significant risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
H
HT Media Ltd
HT Media Ltd shows potential in the evolving media landscape but faces challenges in growth consistency and valuation metrics.
View details
M
Monika Alcobev Ltd
Monika Alcobev Ltd shows potential for growth but faces challenges in valuation and execution risks.
View details
M
Modi Naturals Ltd
Modi Naturals Ltd shows potential in a growing sector, but faces significant challenges in execution and market perception.
View details
C
Commercial Syn Bags Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
V
Vinsys IT Services India Ltd
Vinsys IT Services India Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Kilitch Drugs (India) Ltd is a prominent player in the pharmaceutical sector, specializing in the manufacturing of high-quality generic drugs. With a commitment to excellence, the company caters to both domestic and international markets, ensuring accessibility to vital medications. Kilitch's focus on innovation and stringent quality control makes it a trusted choice for healthcare providers and patients alike. As the demand for affordable healthcare solutions grows, Kilitch stands out as a reliable partner in improving health outcomes.
- Established leader in the pharmaceutical industry
- Specializes in high-quality generic drugs
- Serves both domestic and international markets
- Strong focus on innovation and quality control
- Committed to improving healthcare accessibility
Investment Thesis
Kilitch Drugs (India) Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's strategic initiatives position it well for future success in the pharmaceutical sector.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services provide a robust growth runway in a tech-driven market.
- Valuation metrics indicate Kilitch is attractively priced relative to industry peers.
- Focus on innovation and quality positions the company for long-term success.
- Solid financial performance and consistent dividend history appeal to retail investors.
Opportunity vs Risk
Opportunities
- Growing demand for pharmaceuticals
- Expansion into international markets
- Strong product pipeline
- Government support for healthcare sector
Risks ⚠️
- Regulatory changes affecting operations
- Intense competition in the market
- Currency fluctuations impacting profits
- Dependence on key clients
Peer Perspective
Kilitch Drugs trades at a discount to peers like Sun Pharmaceutical and Lupin, reflecting its lower growth prospects. A rerating could occur if the company demonstrates consistent margin stability and accelerates revenue growth.
Future Outlook
Kilitch Drugs (India) Ltd is well-positioned for growth in the pharmaceutical sector, provided it maintains strong execution and cost control. Continued focus on innovation and market expansion could enhance shareholder value in the coming years.
AI FAQs for Retail Users
- Q: What does Kilitch Drugs (India) Ltd do?A: Kilitch Drugs specializes in manufacturing and exporting pharmaceutical products and formulations.
- Q: Is Kilitch Drugs listed on Indian stock exchanges?A: Yes, Kilitch Drugs is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
- Q: What are the key products of Kilitch Drugs?A: The company primarily offers injectables, tablets, and other pharmaceutical formulations.
- Q: How has Kilitch Drugs performed recently?A: Recent performance can be checked through financial reports and stock market updates.
- Q: What should I consider before investing in Kilitch Drugs?A: Consider the company's financial health, industry trends, and your own investment goals.
📊 Stock Investment Checklist (100 Points)
Kilitch Drugs (India) Ltd • Updated: 2025-09-17 07:13:52
-
10BusinessHighPharmaceutical sector shows growth potential, but competition is high.
-
10GrowthHighRevenue growth has been consistent, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity ratios need improvement.
-
6GovernanceGoodPromoter holding is strong, but some pledging is concerning.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Kilitch Drugs shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100